ZIOPHARM Oncology Stock Price and Value Analysis

Should you buy ZIOPHARM Oncology stock? (NasdaqCM:ZIOP). Let's see how it does in our automated value investing analysis system.

ZIOP Free Cash Flow Trend

Free Cash Flow trendline for ZIOP
Free Cash Flow trendline for ZIOPHARM Oncology

Hmm, we can't give any reliable projection for ZIOPHARM Oncology's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company is solid.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company is not making money.
  • This company pays no dividend.

Inside the ZIOP Numbers

ZIOP Price
(ZIOPHARM Oncology stock price per share)
[?] PE Ratio versus Sector 73% lower than other Healthcare stocks
[?] PE Ratio versus Industry 90% lower than other Biotechnology stocks
[?] Cash Yield -4.31%
[?] Free Cash Flow Jitter 48%

Is ZIOPHARM Oncology Stock on Sale?

Based on our analysis, we believe that you should not buy ZIOPHARM Oncology right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy ZIOP Stock?

Does ZIOPHARM Oncology have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.